NICE funding impacts treatment sequencing patterns in chronic myeloid leukaemia (CML)

  • NICE recommendations determine access to tyrosine kinase inhibitors (TKIs)
  • Median duration of treatment by line also decreased as more TKIs were recommended by NICE
  • Promisingly, the study also found that the proportion of patients in major molecular response increased by line

Click here to read the abstract in the British Journal of Haematology (abstract number: BSH2020‐EP‐027)

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit and contact us at

ref: APR2020LN003